Skip header and navigation

9 records – page 1 of 1.

Document Type
Evidence Search Report
Review Code
PPE041702-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE041702-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Notes
This was never assigned to an RR
Category
Clinical Management
Infection Prevention and Control
Subject
Aerosols
Personal Protective Equipment
Decision Making
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Miller, L; Dalidowicz, M. What is the clinical evidence used to support aerosol generating medical procedures recommendations and guidelines regarding line flow volume or pressure? 2020 Apr 11; Document no.: PPE041702-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
CC210301 ESR
Question Submitted
March 30, 2021
Date Completed
March 31, 2021
Status
3. Completed
Research Team
Critical Care
Document Type
Evidence Search Report
Review Code
CC210301 ESR
Question Submitted
March 30, 2021
Date Completed
March 31, 2021
Status
3. Completed
Research Team
Critical Care
Category
Administration
Clinical Management
Subject
Critical Care
Decision Making
Treatment
Facilities
Population
All
Clinical Setting
ICU
Priority Level
Level 1 2-3 days
Cite As
Young, C; Ellsworth, C. How to deliver remote ICU care for COVID-19 patients to avoid/prevent transfer from smaller communities to tertiary care hospitals. 2021 Mar 31; Document no.: CC210301 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 18 p. (CEST evidence search report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
CC210301 RR
Question Submitted
March 30, 2021
Date Completed
April 6, 2021
Status
3. Completed
Research Team
Critical Care
Document Type
Rapid Review
Review Code
CC210301 RR
Question Submitted
March 30, 2021
Date Completed
April 6, 2021
Status
3. Completed
Research Team
Critical Care
Key Findings
· Tele-ICU services are provided either by existing staff within the network to smaller centers, or outsourced to larger networks or independent firms · The impact of tele-ICU adoption can result in a decrease in ICU mortality as large as 32% · The impact of tele-ICU adoption of length of stay is mixed, with some studies reporting a significant decrease, while others report a small, but statistically insignificant decrease · The degree of impact of tele-ICU adoption is linked to several factors such as yearly admission rates, location (urban vs. rural) and level of authority given to the tele-ICU team leading to increased positive impacts.
Category
Administration
Clinical Management
Subject
Critical Care
Decision Making
Facilities
Treatment
Population
All
Clinical Setting
ICU
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Young, C; Ellsworth, C; Howell-Spooner, B. How to deliver remote ICU care for COVID-19 patients to avoid/prevent transfer from smaller communities to tertiary care hospitals. 2021 Apr 6; Document no.: CC210301 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC210902 ESR
Question Submitted
September 22, 2021
Date Completed
September 29, 2021
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC210902 ESR
Question Submitted
September 22, 2021
Date Completed
September 29, 2021
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Infection Prevention and Control
Subject
Infection Prevention and Control
Health Planning
Decision Making
Vaccination
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L., Howell-Spooner, B. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Sep 29, Document no.: EOC210902 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC210902 RR Table
Question Submitted
September 22, 2021
Date Completed
October 7, 2021
Status
3. Completed
Research Team
EOC
Document Type
Table
Review Code
EOC210902 RR Table
Question Submitted
September 22, 2021
Date Completed
October 7, 2021
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Infection Prevention and Control
Subject
Decision Making
Health Planning
Infection Prevention and Control
Vaccination
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 3 Two weeks (14 days)
Related Documents
Documents

EOC210902 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC210902 RR
Question Submitted
September 22, 2021
Date Completed
October 7, 2021
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC210902 RR
Question Submitted
September 22, 2021
Date Completed
October 7, 2021
Status
3. Completed
Research Team
EOC
Key Findings
Emerging evidence suggesting waning levels of immune markers with time, particularly against more virulent variants. How this will correlate to functional immunity is yet to be documented.
Immunocompromised populations with lower levels of responses to standard 2-dose regimens may benefit from a 3rd dose of mRNA vaccine as a part of the primary series, though their response may still be lower than what is expected in the general population
Current recommendation for populations to receive a 3rd dose include adults over a certain age (depending on jurisdiction), those living in long-term care settings, frontline health and social workers and/or people working in high risk settings, those with immune compromising conditions leading to increased risk of severe disease/poor outcomes if infected
Safety trials have indicated that side effects to 3rd/booster doses are similar to those following the 2nd dose in initial vaccination series
Category
Clinical Management
Infection Prevention and Control
Subject
Decision Making
Health Planning
Infection Prevention and Control
Vaccination
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Badea, A; Groot, G; Muhajarine, N; Lee, S; Shumilak, G; Hernandez-Ronquillo, L; Tian, K. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Oct 07, Document no.: EOC210902 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 8 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC220503 ESR
Question Submitted
May 4, 2022
Date Completed
May 13, 2022
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC220503 ESR
Question Submitted
May 4, 2022
Date Completed
May 13, 2022
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Subject
Infection Prevention and Control
Decision Making
Health Planning
Vaccines
Population
All
Priority Level
Level 3 Two weeks (14 days)
Cite As
Mueller, M; Miller, L. When should post-COVID infected patients receive booster shots? 2022 May 13, Document no.: EOC220503 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 25 p. (CEST evidence search report).
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC220503 RR Table
Question Submitted
May 4, 2022
Date Completed
May 24, 2022
Status
3. Completed
Research Team
EOC
Document Type
Table
Review Code
EOC220503 RR Table
Question Submitted
May 4, 2022
Date Completed
May 24, 2022
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Subject
Infection Prevention and Control
Decision Making
Health Planning
Vaccines
Population
All
Priority Level
Level 3 Two weeks (14 days)
Cite As
Badea, A; Groot, G; Reeder, B; Mueller, M; Miller, L. When should post-COVID infected patients receive booster shots? 2022 May 24, Document no.: EOC220503 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

EOC220503 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC220503 RR
Question Submitted
May 4, 2022
Date Completed
May 24, 2022
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC220503 RR
Question Submitted
May 4, 2022
Date Completed
May 24, 2022
Status
3. Completed
Research Team
EOC
Key Findings
Most public health guidance recommends a deferral of 3 months following infection, in addition to meeting other eligibility criteria for booster COVID-19 administration
Several antibody titer studies indicate a longer interval between infection and vaccination could produce a stronger antibody response
Category
Clinical Management
Subject
Infection Prevention and Control
Decision Making
Health Planning
Vaccines
Population
All
Priority Level
Level 3 Two weeks (14 days)
Cite As
Badea, A; Groot, G; Reeder, B; Mueller, M; Miller, L. When should post-COVID infected patients receive booster shots? 2022 May 24, Document no.: EOC220503 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST rapid review report).
Related Documents
Documents
Less detail

9 records – page 1 of 1.